alexa New Leads for Personalized Medicine in Pediatrics: Targeting Syk for Treatment of Serious Pediatric Illnesses | Open Access Journals
ISSN: 2161-0665
Pediatrics & Therapeutics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

New Leads for Personalized Medicine in Pediatrics: Targeting Syk for Treatment of Serious Pediatric Illnesses

Vikki Stefans*

Associate Professor, Department of Pediatrics and PM&R, Arkansas Children’s Hospital, USA

*Corresponding Author:
Fatih M. Uckun
Professor of Pediatrics
University of Southern California Keck School of Medicine
Head, Translational Research in Leukemia and Lymphoma
Children’s Center for Cancer and Blood Diseases
CHLA, Los Angeles, CA, USA
E-mail: [email protected]

Received Date: April 08, 2012; Accepted Date: April 10, 2012; Published Date: April 11, 2012

Citation: Uckun FM (2012) New Leads for Personalized Medicine in Pediatrics: Targeting Syk for Treatment of Serious Pediatric Illnesses. Pediat Therapeut 2:e109. doi:10.4172/2161-0665.1000e109

Copyright: © 2012 Uckun FM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pediatrics & Therapeutics

Spleen tyrosine kinase (SYK), a key regulator of signal transduction pathways in lymphohematopoietic cells and mast cells has emerged as a potential molecular target for treatment of serious pediatric illnesses, including acute lymphoblastic leukemia, the most common form of childhood cancer [1], acute myeloid leukemia [2], autoimmune diseases [3-5], inflammatory disorders [4,5], allergic disorders and asthma [5,6], and graft versus host disease after hematopoietic stem cell transplantation [7]. Notably, a meta-analysis using the Oncomine database revealed a marked enrichment of the most discriminating SYKdependent anti-apoptotic genes in 18 diagnostic classes of leukemias and lymphomas [1]. More recent studies revealed overexpression of SYK in retinoblastoma [8].

Several structurally distinct and highly potent small molecule inhibitors of SYK tyrosine kinase ATP binding site have been developed [9-13]. A pentapeptide mimic targeting the substrate binding P-site of SYK tyrosine kinase has been shown to act as a potent inducer of apoptosis in chemotherapy-resistant SYK-expressing primary leukemic B-cell precursors taken directly from relapsed pediatric ALL patients, exhibit favorable pharmacokinetics in mice and non-human primates, and eradicate in vivo clonogenic leukemia cells in SCID mouse xenograft models of chemotherapy-resistant human ALL at dose levels non-toxic to mice and non-human primates [10]. In addition to small molecule tyrosine kinase inhibitors, antisense oligonucleotides and small interfering RNAs (siRNAs) have also been developed to knock down SYK expression [14,15].

The efficient delivery of the various SYK inhibitors by leveraging nanotechnology holds particular promise. Liposomal nanoparticle therapeutics containing active anti-cancer agents may provide the foundation for potentially more effective and less toxic anti-cancer treatment strategies due to their improved pharmacokinetics, reduced systemic toxicity, and increased intra-tumoral/intra-cellular delivery [16-18]. Nanoparticles have been coated with polyethylene glycol (PEG) (i.e. PEGylated) in an attempt to render them resistant against protein adsorption, enhance their biocompatibility, and to stabilize them against agglomeration in biological environments. PEGylated nanoparticles with diameters around 100-nm may become longcirculating in the blood stream and have been called stealth particles since they can evade recognition by T-cells and macrophages and avoid rapid clearance by the immune system [16-18]. Nanoparticles that are sterically stabilized by PEG polymers on their surface and have surface charges that are slightly negative or slightly positive have minimal self-self or self-non-self interactions and improved pharmacokinetics. PEGylation of nanoparticles creates a hydrophilic surface and leads to increased protein solubility, reduced immunogenicity, prolonged plasma half life due to prevention of rapid renal clearance, and reduced clearance by the RES system due to decreased macrophage capture and opsonization [16-18]. The rationally engineered nanoparticle constructs of SYK inhibitors are likely to be less toxic and more effective than free molecules.

Nanoparticles can be functionalized with a tumor targeting moiety such as a ligand or scFv directed against a surface receptor on cancer cells in order to achieve optimal tumor targeting and site-specific drug delivery to further reduce their toxicity and improve their efficacy [16-18]. When linked with tumor targeting moieties nanoparticles can reach cancer cells carrying the target receptors with high affinity and precision. The targeting ligands enable nanoparticles to bind to cell surface receptors and enter cells by receptor-mediated endocytosis. In our own program, efforts are underway to prepare nanoparticles targeted against the CD19 antigen on childhood leukemia cells. Further development of rationally designed SYK inhibitors and their nanoscale formulations may provide the foundation for therapeutic innovation against a broad spectrum of serious pediatric diseases.

Acknowledgements

F.M.U is supported by DHHS/NIH grants U01-CA-151837, R01-CA-154471, Couples against Leukemia Foundation and a V Foundation Translational Research Grant.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Article Usage

  • Total views: 11545
  • [From(publication date):
    August-2012 - Nov 19, 2017]
  • Breakdown by view type
  • HTML page views : 7790
  • PDF downloads : 3755
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]line.com

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords